CP-122721

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H23F3N2O2
Molecular Weight	380.404
Optical Activity	( + )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(OC(F)(F)F)C=C1CN[C@H]2CCCN[C@H]2C3=CC=CC=C3

InChI

InChIKey=ZIWFCOIGUNPHPM-HKUYNNGSSA-N

InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H23F3N2O2
Molecular Weight	380.404
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:07:47 UTC 2023` Edited by `admin` on `Fri Dec 15 18:07:47 UTC 2023`
Record UNII	R7OYP6N58F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CP-122721

Common Name

English

CP-122,721

Code

English

(+)-CP-122,721

Code

English

(2S,3S)-2-PHENYL-3-((5-TRIFLUOROMETHOXY-2-METHOXY)BENZYLAMINO)PIPERIDINE

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID9047251

Created by admin on Fri Dec 15 18:07:48 UTC 2023 , Edited by admin on Fri Dec 15 18:07:48 UTC 2023

PRIMARY

DRUG BANK

DB05421

Created by admin on Fri Dec 15 18:07:48 UTC 2023 , Edited by admin on Fri Dec 15 18:07:48 UTC 2023

PRIMARY

CAS

145742-28-5

Created by admin on Fri Dec 15 18:07:48 UTC 2023 , Edited by admin on Fri Dec 15 18:07:48 UTC 2023

PRIMARY

FDA UNII

R7OYP6N58F

Created by admin on Fri Dec 15 18:07:48 UTC 2023 , Edited by admin on Fri Dec 15 18:07:48 UTC 2023

PRIMARY

PUBCHEM

9821217

Created by admin on Fri Dec 15 18:07:48 UTC 2023 , Edited by admin on Fri Dec 15 18:07:48 UTC 2023

PRIMARY

Related Record Type Details


					6OU487748Q

SUBSTANCE-P RECEPTOR

TARGET -> INHIBITOR

Interaction Type:

SELECTIVE

Amount:


					225C5779IV

CP-122721 DIHYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					9YK2LD29LN

.BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-(AMINOMETHYL)-4-(TRIFLUOROMETHOXY)PHENYL

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					NDL1FEY5R9

.BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((((2S,3S)-2-PHENYL-3-PIPERIDINYL)AMINO)METHYL)-4-(TRIFLUOROMETHOXY)PHENYL

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					4QTV2LM2F8

.BETA.-D-GLUCOPYRANOSIDURONIC ACID, (2-HYDROXY-5-(TRIFLUOROMETHOXY)PHENYL)METHYL

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					5BU4YE0JNW

2,4-PIPERIDINEDIONE, 5-(((2-METHOXY-5-(TRIFLUOROMETHOXY)PHENYL)METHYL)AMINO)-6-PHENYL-, (5R,6S)-

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					GXF18XW0VP

.BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((((2S,3S)-6-OXO-2-PHENYL-3-PIPERIDINYL)AMINO)METHYL)-4-(TRIFLUOROMETHOXY)PHENYL

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					9KB1DMK0VJ

2-(AMINOMETHYL)-4-(TRIFLUOROMETHOXY)PHENYLSULFATE

METABOLITE -> PARENT

Comments:

IN EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					5U7H38I0VB

2-HYDROXY-5-(TRIFLUOROMETHOXY)BENZOIC ACID

METABOLITE -> PARENT

Comments:

IN POOR METABOLIZER HUMAN SUBJECTS

Qualification:

URINE

Amount:


					32L96T2257

(5S,6S)-5-(((2-HYDROXY-5-(TRIFLUOROMETHOXY)PHENYL)METHYL)AMINO)-6-PHENYL-2-PIPERIDINONE

METABOLITE -> PARENT

Comments:

IN POOR METABOLIZER HUMAN SUBJECTS

Qualification:

FECAL

Amount:


					J41VUN24GM

CP-125611

METABOLITE -> PARENT

Comments:

IN TWO EXTENSIVE METABOLIZER HUMAN SUBJECTS

Qualification:

FECAL

Amount:

Related Record Type Details


					R7OYP6N58F

CP-122721

ACTIVE MOIETY

Amount:

Name	Property Type	Parameters
Biological Half-life	PHARMACOKINETIC	ORAL ADMINISTRATION IN EXTENSIVE METABOLIZERS

Biological Half-life	PHARMACOKINETIC	IN POOR METABOLIZERS ORAL ADMINISTRATION